Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
ESMO Open|March 19, 2025
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patientsS Gupta, M A Climent Duran, S S Sridhar, et al.
British Journal of Cancer|April 10, 2014
Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancerH-M Lin, L Castillo, K L Mahon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)P S Grimison, M R Stockler, M Chatfield, et al.
Clinical Pharmacology and Therapeutics|February 26, 2014
Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662M H M Diekstra, H J Klümpen, M P J K Lolkema, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2024
Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinomaN Agarwal, J Brugarolas, P Ghatalia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2024
Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinomaR J Motzer, C Porta, M Eto, et al.
ESMO Open|April 20, 2024
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trialT Powles, M Burotto, B Escudier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2025
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trialR J Motzer, B Escudier, M Burotto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2025
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 studyJ N Graff, M Burotto, P C Fong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2019
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-upY Fradet, J Bellmunt, D J Vaughn, et al.
Pageof 6